JP7459075B2 - スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 - Google Patents

スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 Download PDF

Info

Publication number
JP7459075B2
JP7459075B2 JP2021519609A JP2021519609A JP7459075B2 JP 7459075 B2 JP7459075 B2 JP 7459075B2 JP 2021519609 A JP2021519609 A JP 2021519609A JP 2021519609 A JP2021519609 A JP 2021519609A JP 7459075 B2 JP7459075 B2 JP 7459075B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
aureus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519609A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020076790A5 (enExample
JP2022512646A (ja
Inventor
トカジク，クリスティーン
セルマン，ブレット
ド，クン
ダムシュローダー，メリッサ
コルティ，ダヴィデ
ミノラ，アンドレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2022512646A publication Critical patent/JP2022512646A/ja
Publication of JPWO2020076790A5 publication Critical patent/JPWO2020076790A5/ja
Application granted granted Critical
Publication of JP7459075B2 publication Critical patent/JP7459075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021519609A 2018-10-09 2019-10-08 スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 Active JP7459075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743501P 2018-10-09 2018-10-09
US62/743,501 2018-10-09
PCT/US2019/055144 WO2020076790A1 (en) 2018-10-09 2019-10-08 Antibodies directed against staphylococcus aureus leukotoxins

Publications (3)

Publication Number Publication Date
JP2022512646A JP2022512646A (ja) 2022-02-07
JPWO2020076790A5 JPWO2020076790A5 (enExample) 2022-10-18
JP7459075B2 true JP7459075B2 (ja) 2024-04-01

Family

ID=68393067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519609A Active JP7459075B2 (ja) 2018-10-09 2019-10-08 スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体

Country Status (11)

Country Link
US (2) US11059884B2 (enExample)
EP (1) EP3864040A1 (enExample)
JP (1) JP7459075B2 (enExample)
KR (1) KR20210080411A (enExample)
CN (1) CN113015745B (enExample)
AU (1) AU2019359207A1 (enExample)
BR (1) BR112021006704A2 (enExample)
CA (1) CA3115765A1 (enExample)
MX (1) MX2021004114A (enExample)
TW (1) TWI895248B (enExample)
WO (1) WO2020076790A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
BR112021006704A2 (pt) 2018-10-09 2021-08-10 Medimmune, Llc anticorpos dirigidos contra leucotoxinas de staphylococcus aureus
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
JP7682795B2 (ja) 2019-03-13 2025-05-26 メディミューン，エルエルシー コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減
CN113493510A (zh) * 2021-07-07 2021-10-12 上海交通大学 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用
CN113583119B (zh) * 2021-07-07 2023-05-02 西北农林科技大学 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535985A (ja) 2013-10-17 2016-11-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
JP2022512647A (ja) 2018-10-09 2022-02-07 メディミューン，エルエルシー 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
EP2126087A4 (en) 2007-02-20 2010-10-27 Anaptysbio Inc METHODS FOR PRODUCING PHARMACOTHEQUES, AND USES THEREOF
CA2749200A1 (en) 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
MX386545B (es) 2010-05-05 2025-03-19 Univ New York Leucocidinas de staphylococcus aureus, composiciones terapéuticas y usos de las mismas.
HRP20182017T4 (hr) 2011-02-08 2021-08-20 Medimmune, Llc Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
MX367082B (es) 2012-11-06 2019-08-05 Medimmune Llc Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
KR20170136637A (ko) 2015-04-17 2017-12-11 알사니스 바이오사이언시스 게엠베하 항-스타필로코커스 아우레우스 항체 배합 제제
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
BR112021006704A2 (pt) 2018-10-09 2021-08-10 Medimmune, Llc anticorpos dirigidos contra leucotoxinas de staphylococcus aureus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535985A (ja) 2013-10-17 2016-11-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
JP2022512647A (ja) 2018-10-09 2022-02-07 メディミューン，エルエルシー 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mAbs，2015年，Vol.7, No.1，p.243-254

Also Published As

Publication number Publication date
US20210363229A1 (en) 2021-11-25
US20200109190A1 (en) 2020-04-09
US11578119B2 (en) 2023-02-14
CN113015745A (zh) 2021-06-22
CA3115765A1 (en) 2020-04-16
WO2020076790A1 (en) 2020-04-16
BR112021006704A2 (pt) 2021-08-10
TW202028232A (zh) 2020-08-01
KR20210080411A (ko) 2021-06-30
US11059884B2 (en) 2021-07-13
AU2019359207A1 (en) 2021-05-20
JP2022512646A (ja) 2022-02-07
CN113015745B (zh) 2025-02-11
EP3864040A1 (en) 2021-08-18
TWI895248B (zh) 2025-09-01
MX2021004114A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
JP7459075B2 (ja) スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体
US11970527B2 (en) Antibody directed against S. aureus clumping factor A (ClfA)
KR102840867B1 (ko) 치료용 항-cd40 리간드 항체
US11168133B2 (en) Combinations of anti-Staphylococcus aureus antibodies
KR102557216B1 (ko) 그렘린-1 결정 구조 및 억제 항체
WO2014028748A1 (en) Interleukin 2 antibodies and antibody complexes
JPWO2019131769A1 (ja) 新規抗ｐａｄ４抗体
RU2805969C2 (ru) Антитела, направленные против лейкотоксинов staphylococcus aureus
WO2021186398A1 (en) Anti-klebsiella pneumoniae antibodies and uses thereof
RU2818805C2 (ru) АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus
TWI902669B (zh) 抗金黃色葡萄球菌凝集因子a(clfa)之抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210526

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7459075

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150